ERK Inhibitors

ERK

ERK1

ERK2

ERK5

ERK8

ERK Degraders, Inhibitors & Activators

Product Name	ERK	ERK1	ERK2	ERK5	ERK8	Purity
Yoda 1		ERK1	ERK2			99.98%
PD98059		ERK1	ERK2			99.96%
SCH772984		ERK1, IC₅₀: 4 nM	ERK2, IC₅₀: 1 nM			99.83%
Tauroursodeoxycholate	ERK					99.93%
TBHQ	ERK					99.89%
β-Glycerophosphate disodium salt pentahydrate		ERK1	ERK2			99.81%
Astragaloside IV		ERK1	ERK2			99.93%
Ulixertinib			ERK2, IC₅₀: 0.3 nM (at K_M ATP (60 μM))			99.95%
Honokiol		ERK1	ERK2			99.90%
C16-PAF	ERK					99.85%
L-Cysteine		ERK1	ERK2
Tauroursodeoxycholate sodium	ERK					98.40%
Temuterkib		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 5 nM			99.94%
Piperlongumine		ERK1	ERK2			99.87%
β-Glycerophosphate disodium salt hydrate		ERK1	ERK2			≥98.0%
Ravoxertinib		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.75%
Lysophosphatidylcholines		ERK1	ERK2			≥99.0%
Lidocaine	ERK					99.96%
Gamma-Linolenic acid		ERK1	ERK2			99.80%
trans-Zeatin	ERK					99.60%
Fucoxanthin			ERK2			98.99%
FR 180204		ERK1, Ki: 0.31 μM ERK1, IC₅₀: 0.51 μM	ERK2, Ki: 0.14 μM ERK2, IC₅₀: 0.33 μM			99.91%
ASN007		ERK1	ERK2			99.70%
6-OAU	ERK					99.77%
Pachymic acid	ERK					99.94%
LM22B-10	ERK					99.92%
BIX02189				ERK5, IC₅₀: 59 nM		99.93%
Lidocaine hydrochloride	ERK					99.84%
XMD8-92				BMK1, Kd: 80 nM		99.48%
MK-8353		ERK1, IC₅₀: 23 nM	ERK2, IC₅₀: 8.8 nM			98.13%
VX-11e			ERK2, Ki: 2 nM			98.94%
Peiminine		ERK1	ERK2			99.94%
AG126			ERK2			≥98.0%
Peramivir		ERK1	ERK2			99.32%
TERT activator-1		ERK1	ERK2			99.50%
ASTX029		ERK1	ERK2			99.86%
Pluripotin		ERK1, Kd: 98 nM				98.86%
ERK1/2 inhibitor 1			ERK2, IC₅₀: 3.0 nM			99.58%
Broussonin E	ERK					98.18%
AX-15836				ERK5, IC₅₀: 8 nM		99.79%
Lidocaine (Standard)	ERK					99.85%
Cafestol			ERK2			99.91%
CHPG sodium salt	ERK					99.25%
H-Ile-Lys-Val-Ala-Val-OH		ERK1	ERK2			99.42%
Tizaterkib			ERK2, IC₅₀: 0.6 nM			99.31%
CC-90003		ERK1	ERK2			99.71%
ERK5-IN-1				ERK5, IC₅₀: 87 nM		99.55%
Methylnissolin		ERK1	ERK2			99.86%
Ravoxertinib hydrochloride		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.44%
DEL-22379			ERK2, IC₅₀: 0.5 μM			99.69%
JWG-071				ERK5, IC₅₀: 88 nM		99.15%
KO-947		ERK1	ERK2			99.61%
MAP855	ERK, EC₅₀: 5 nM					98.48%
ASN007 benzenesulfonate		ERK1	ERK2			99.72%
Rineterkib		ERK1	ERK2			99.83%
Mogrol		ERK1	ERK2			99.76%
XMD17-109				ERK5, IC₅₀: 162 nM		99.20%
CK2/ERK8-IN-1					ERK8, IC₅₀: 0.5 μM	≥99.0%
ERK5-IN-2				ERK5, IC₅₀: 0.82 μM ERK5 MEF2D, IC₅₀: 3 μM		98.96%
β-Neo-Endorphin		ERK1	ERK2			99.32%
BIX02188				ERK5, IC₅₀: 810 nM		99.85%
CHPG	ERK					99.51%
Sanggenon C	ERK					98.46%
HIOC	ERK					99.94%
AT-533		ERK1	ERK2			98.86%
Lidocaine hydrochloride hydrate	ERK					99.90%
4-Methylbenzylidene camphor		ERK1	ERK2			99.87%
Corynoxeine		ERK1	ERK2			99.97%
2,5-Dihydroxyacetophenone		ERK1	ERK2			99.89%
Magnolin		ERK1, IC₅₀: 87 nM	ERK2, IC₅₀: 16.5 nM			99.98%
Trimebutine maleate		ERK1	ERK2			99.91%
Loureirin B	ERK					99.95%
ERK-IN-4			ERK2, Kd: 5 μM			99.61%
Myristicin	ERK					99.89%
CKLF1-C27		ERK1	ERK2			98.46%
Longdaysin			ERK2, IC₅₀: 52 μM			99.83%
Cearoin	ERK					≥98.0%
Methylthiouracil		ERK1	ERK2			≥98.0%
Deltonin		ERK1	ERK2			99.94%
Enniatin B1	ERK					99.34%
Omtriptolide	ERK
Trimebutine		ERK1	ERK2			99.42%
BAY885				ERK5, IC₅₀: 35 nM		99.27%
[Tyr8] Bradykinin		ERK1	ERK2			99.61%
Anti-inflammatory agent 35	ERK					99.77%
EVT801	ERK, IC₅₀: 13 nM
Isoprocurcumenol	ERK
ML192		ERK1	ERK2
ERK1/2 inhibitor 9		ERK1	ERK2
SHR2415		ERK1, IC₅₀: 2.8 nM	ERK2, IC₅₀: 5.9 nM			98.63%
ERK5-IN-5				ERK5		99.05%
Syk-IN-6		ERK1	ERK2
Hypothemycin		ERK1, Ki: 8.4 μM	ERK2, Ki: 2.4 μM			≥98.0%
Sugiol		ERK1	ERK2			99.88%
Bohemine			ERK2, IC₅₀: 52 μM			98.93%
Enniatin B	ERK					99.86%
Fulipiftide			ERK2
PT-262	ERK					99.21%
ERK-IN-2			ERK2, IC₅₀: 1.8 nM
ERK5-IN-6	ERK
Cudraflavone B	ERK
Anti-inflammatory agent 31		ERK1	ERK2
CKLF1-C27 TFA		ERK1	ERK2
MK2-IN-5		ERK1	ERK2
ERK5-IN-3				ERK5, IC₅₀: 6 ± 1 nM
Trimebutine-d₃ hydrochloride		ERK1	ERK2
Anticancer agent 231		ERK1	ERK2
ERK2-IN-4			ERK2, Ki: 0.006 μM
PPM-3				ERK5, IC₅₀: 62.4 ± 18. nM
Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK, IC₅₀: 13 μM (The in vivo inhibitory potency is determined in both PMA-treated NIH 3T3 cells and NGF-stimulated PC12 cells.)		ERK2, IC₅₀: 10 μM (The in vitro inhibitory potency of the peptides is measured based on their ability to inhibit MEK1-mediated phosphorylation of ERK2. )
ERK1/2 inhibitor 13		ERK1, IC₅₀: 91.71 nM	ERK2, IC₅₀: 97.87 nM
ERK-IN-7		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 7 nM
DCZ19931		ERK1	ERK2
ERK2-IN-6			ERK2, IC₅₀: 7.9 nM
ZINC12409120	ERK, IC₅₀: 5 μM
Aloisine A		ERK1, IC₅₀: 18 μM	ERK2, IC₅₀: 22 μM
ERK5-IN-4				ERK5
ERK-IN-8			ERK2, IC₅₀: ≤50 nM
ERK-IN-2 free base			ERK2, IC₅₀: 1.8 nM
Enniatin A1	ERK
CXJ-2	ERK
ERK2 IN-5			ERK2, Ki: 86 nM
ERK1/2 inhibitor 10		ERK1, IC₅₀: 0.11 nM	ERK2, IC₅₀: 0.8 nM
Trimebutine-d₅ fumarate		ERK1	ERK2
MHJ-627				ERK5
ERK2 allosteric-IN-1			ERK2, IC₅₀: 11 μM
Phenylhydroquinone		ERK1	ERK2			99.21%
Tizaterkib (hexanedioic acid)			ERK2, IC₅₀: 0.6 nM
Methyl helicterate		ERK1	ERK2
(3S)-Tanzisertib hydrochloride		ERK1, IC₅₀: 0.48 μM
Trimebutine maleate (Standard)		ERK1	ERK2
Trimebutine (Standard)		ERK1	ERK2
ERK2 IN-1			ERK2, IC₅₀: 7 nM
Hexachlorobenzene		ERK1	ERK2

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4